Clinical Trial

A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary purpose of this Phase II study is to evaluate the preliminary anti-tumor efficacy of HF1K16 in combination with Bevacizumab in patients with recurrent or progressive glioma. The study also evaluates the safety and tolerability of the combination therapy.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-11
Trial Details
NCT Number NCT07678684
Lead Sponsor HighField Biopharmaceuticals Corporation
Conditions Glioma, Adult
Enrollment 30 participants
Start Date 2026-06-30
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-10